JP2011507879A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011507879A5 JP2011507879A5 JP2010539763A JP2010539763A JP2011507879A5 JP 2011507879 A5 JP2011507879 A5 JP 2011507879A5 JP 2010539763 A JP2010539763 A JP 2010539763A JP 2010539763 A JP2010539763 A JP 2010539763A JP 2011507879 A5 JP2011507879 A5 JP 2011507879A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- composition
- compound according
- pharmaceutically acceptable
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 76
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 27
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 150000002148 esters Chemical class 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 23
- 239000011780 sodium chloride Substances 0.000 claims description 23
- 239000012453 solvate Substances 0.000 claims description 23
- 239000000651 prodrug Substances 0.000 claims description 22
- 229940002612 prodrugs Drugs 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 230000002265 prevention Effects 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 12
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 239000003380 propellant Substances 0.000 claims description 8
- 239000002464 receptor antagonist Substances 0.000 claims description 8
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims description 7
- 230000001387 anti-histamine Effects 0.000 claims description 6
- 239000000739 antihistaminic agent Substances 0.000 claims description 6
- 201000008937 atopic dermatitis Diseases 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 230000003042 antagnostic Effects 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims description 5
- 208000006673 Asthma Diseases 0.000 claims description 4
- 206010003816 Autoimmune disease Diseases 0.000 claims description 4
- 208000006897 Interstitial Lung Disease Diseases 0.000 claims description 4
- 208000006641 Skin Disease Diseases 0.000 claims description 4
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 201000009890 sinusitis Diseases 0.000 claims description 4
- 125000005466 alkylenyl group Chemical group 0.000 claims description 3
- -1 anti-infectives Substances 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000002757 inflammatory Effects 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- OIRDTQYFTABQOQ-GAWUUDPSSA-N 9-β-D-XYLOFURANOSYL-ADENINE Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O OIRDTQYFTABQOQ-GAWUUDPSSA-N 0.000 claims description 2
- 229940005497 ANTICHOLINERGIC AGENTS Drugs 0.000 claims description 2
- 229940074728 ANTIINFECTIVE OPHTHALMOLOGICS Drugs 0.000 claims description 2
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 claims description 2
- 208000002205 Allergic Conjunctivitis Diseases 0.000 claims description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims description 2
- 229940021383 Antiinfective irrigating solutions Drugs 0.000 claims description 2
- 229960005475 Antiinfectives Drugs 0.000 claims description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims description 2
- 206010006451 Bronchitis Diseases 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 2
- 108010059108 CD18 Antigens Proteins 0.000 claims description 2
- 208000007451 Chronic Bronchitis Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
- 206010012434 Dermatitis allergic Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 208000005679 Eczema Diseases 0.000 claims description 2
- 229940066493 Expectorants Drugs 0.000 claims description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 claims description 2
- 102000019223 Interleukin-1 receptor family Human genes 0.000 claims description 2
- 108050006617 Interleukin-1 receptor family Proteins 0.000 claims description 2
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims description 2
- 210000004072 Lung Anatomy 0.000 claims description 2
- 102100000918 MAPK14 Human genes 0.000 claims description 2
- 102100002496 NOS2 Human genes 0.000 claims description 2
- 101700049309 NOS2 Proteins 0.000 claims description 2
- 208000000592 Nasal Polyps Diseases 0.000 claims description 2
- 210000001331 Nose Anatomy 0.000 claims description 2
- 206010068318 Oropharyngeal discomfort Diseases 0.000 claims description 2
- 210000003800 Pharynx Anatomy 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 2
- 206010039083 Rhinitis Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 208000003385 Rhinitis, Allergic, Seasonal Diseases 0.000 claims description 2
- 102000000551 Syk Kinase Human genes 0.000 claims description 2
- 108010016672 Syk Kinase Chemical class 0.000 claims description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims description 2
- 229960005305 adenosine Drugs 0.000 claims description 2
- 239000000048 adrenergic agonist Substances 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 2
- 230000002009 allergen Effects 0.000 claims description 2
- 230000000172 allergic Effects 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000002924 anti-infective Effects 0.000 claims description 2
- 230000000840 anti-viral Effects 0.000 claims description 2
- 239000000043 antiallergic agent Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 229940121357 antivirals Drugs 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 125000005418 aryl aryl group Chemical group 0.000 claims description 2
- 230000003115 biocidal Effects 0.000 claims description 2
- 210000002449 bone cell Anatomy 0.000 claims description 2
- 239000002617 bone density conservation agent Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 239000000812 cholinergic antagonist Substances 0.000 claims description 2
- 239000006184 cosolvent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 239000002619 cytotoxin Substances 0.000 claims description 2
- 239000000850 decongestant Substances 0.000 claims description 2
- 201000004624 dermatitis Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229940079593 drugs Drugs 0.000 claims description 2
- 231100001003 eczema Toxicity 0.000 claims description 2
- 230000003419 expectorant Effects 0.000 claims description 2
- 239000003172 expectorant agent Substances 0.000 claims description 2
- 125000006492 halo alkyl aryl group Chemical group 0.000 claims description 2
- 125000005842 heteroatoms Chemical group 0.000 claims description 2
- 230000001861 immunosuppresant Effects 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 229940079866 intestinal antibiotics Drugs 0.000 claims description 2
- 150000002617 leukotrienes Chemical class 0.000 claims description 2
- 230000001404 mediated Effects 0.000 claims description 2
- 201000009053 neurodermatitis Diseases 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 claims description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims description 2
- 229940005943 ophthalmologic Antivirals Drugs 0.000 claims description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
- 201000004681 psoriasis Diseases 0.000 claims description 2
- 239000000018 receptor agonist Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 230000000699 topical Effects 0.000 claims description 2
- 229940026754 topical Antivirals Drugs 0.000 claims description 2
- 150000003751 zinc Chemical class 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 150000002431 hydrogen Chemical class 0.000 description 8
- 200000000018 inflammatory disease Diseases 0.000 description 3
- 208000009745 Eye Disease Diseases 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 0 C*OC(c1ccccc1)OS Chemical compound C*OC(c1ccccc1)OS 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- 206010021425 Immune system disease Diseases 0.000 description 1
- YEESKJGWJFYOOK-IJHYULJSSA-N Leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 201000006704 ulcerative colitis Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1614407P | 2007-12-21 | 2007-12-21 | |
| PCT/US2008/087301 WO2009085880A2 (en) | 2007-12-21 | 2008-12-18 | C-21 thioethers as glucocorticoid receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011507879A JP2011507879A (ja) | 2011-03-10 |
| JP2011507879A5 true JP2011507879A5 (fi) | 2012-02-02 |
Family
ID=40513892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010539763A Pending JP2011507879A (ja) | 2007-12-21 | 2008-12-18 | グルココルチコイド受容体アゴニストとしてのｃ−２１チオエーテル |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110262368A1 (fi) |
| EP (1) | EP2235035A2 (fi) |
| JP (1) | JP2011507879A (fi) |
| CN (1) | CN102099368A (fi) |
| AR (1) | AR070040A1 (fi) |
| CA (1) | CA2710240A1 (fi) |
| CL (1) | CL2008003802A1 (fi) |
| MX (1) | MX2010007024A (fi) |
| PE (1) | PE20091215A1 (fi) |
| TW (1) | TW200940070A (fi) |
| WO (1) | WO2009085880A2 (fi) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101970452A (zh) * | 2007-12-21 | 2011-02-09 | 先灵公司 | C20-c21取代的糖皮质激素受体激动剂 |
| UY32520A (es) | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides |
| CN103694306B (zh) * | 2014-01-07 | 2016-03-23 | 成都医路康医学技术服务有限公司 | 一种布地奈德s异构体制备r异构体的方法 |
| CA3025377A1 (en) | 2016-06-02 | 2017-12-07 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
| US10711032B2 (en) | 2016-11-08 | 2020-07-14 | Regeneron Pharmaceuticals, Inc. | Steroids and protein-conjugates thereof |
| MX2019013690A (es) | 2017-05-18 | 2020-01-27 | Regeneron Pharma | Conjugados de farmaco-proteina con ciclodextrina. |
| IL274427B2 (en) | 2017-11-07 | 2024-11-01 | Regeneron Pharmaceuticals Inc | Hydrophilic linkers for drug-antibody conjugates |
| SI3658192T1 (sl) | 2017-12-01 | 2021-08-31 | Abbvie Inc. | Agonist glukokortikoidnega receptorja in njegovi imunokonjugati |
| KR20200108002A (ko) | 2018-01-08 | 2020-09-16 | 리제너론 파마슈티칼스 인코포레이티드 | 스테로이드 및 이의 항체-접합체 |
| EP3790899A1 (en) | 2018-05-09 | 2021-03-17 | Regeneron Pharmaceuticals, Inc. | Anti-msr1 antibodies and methods of use thereof |
| EP3868368A1 (en) * | 2020-02-21 | 2021-08-25 | Dompe' Farmaceutici S.P.A. | Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof |
| WO2024125639A1 (zh) * | 2022-12-16 | 2024-06-20 | 津药生物科技（天津）有限公司 | 新型糖皮质激素、其制备方法及用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2231374B1 (fi) * | 1973-05-30 | 1976-10-22 | Jouveinal Sa | |
| FR2510582B1 (fr) * | 1981-07-30 | 1986-05-30 | Sipsy | Steroides esterifies en la position 17 et thio-esterifies en la position 21, leur procede de preparation et leur application comme medicament |
| FR2551069B1 (fr) * | 1983-08-26 | 1986-07-25 | Jouveinal Sa | 17-oxo-21-thioesters d'hydrocortisone, leur preparation et leurs applications comme medicament |
| US5223493A (en) * | 1984-12-28 | 1993-06-29 | Alcon Laboratories, Inc. | Anti-inflammatory compounds for ophthalmic use |
| US4861765A (en) * | 1985-06-26 | 1989-08-29 | Jouveinal | 21-alkyl-, cycloalkyl- or aryl-substituted thio steroids and pharmaceutical compositions containing them |
| US5420120A (en) * | 1993-12-17 | 1995-05-30 | Alcon Laboratories, Inc. | Anti-inflammatory glucocorticoid compounds for topical ophthalmic use |
| ES2150151T3 (es) * | 1995-12-29 | 2000-11-16 | Glaxo Group Ltd | Derivados de 21-(2-oxo-tetrahidrofuran)-tio-pregnano, un procedimiento para su produccion y composiciones farmaceuticas que los contienen. |
| US20100209508A1 (en) * | 2005-06-14 | 2010-08-19 | Corus Pharma, Inc. | Substituted Phenylphosphates as Mutual Prodrugs of Steroids and ß-Agonists for the Treatment of Title Pulmonary Inflammation and Bronchoconstriction |
| CN101970452A (zh) * | 2007-12-21 | 2011-02-09 | 先灵公司 | C20-c21取代的糖皮质激素受体激动剂 |
-
2008
- 2008-12-18 MX MX2010007024A patent/MX2010007024A/es not_active Application Discontinuation
- 2008-12-18 TW TW097149503A patent/TW200940070A/zh unknown
- 2008-12-18 US US12/736,064 patent/US20110262368A1/en not_active Abandoned
- 2008-12-18 WO PCT/US2008/087301 patent/WO2009085880A2/en active Application Filing
- 2008-12-18 JP JP2010539763A patent/JP2011507879A/ja active Pending
- 2008-12-18 PE PE2008002135A patent/PE20091215A1/es not_active Application Discontinuation
- 2008-12-18 CN CN2008801273009A patent/CN102099368A/zh active Pending
- 2008-12-18 CL CL2008003802A patent/CL2008003802A1/es unknown
- 2008-12-18 CA CA2710240A patent/CA2710240A1/en not_active Abandoned
- 2008-12-18 EP EP08866275A patent/EP2235035A2/en not_active Withdrawn
- 2008-12-18 AR ARP080105526A patent/AR070040A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011507879A5 (fi) | ||
| JP2011507878A5 (fi) | ||
| US9102619B2 (en) | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | |
| JP5084736B2 (ja) | 肺高血圧を処置するためのジアリールウレア | |
| EP2447253B1 (en) | Dihydropyrimidine compounds, preparation methods, pharmaceutical compositions thereof and their use as antiviral agents | |
| JP5008778B2 (ja) | 新規５−フルオロウラシル誘導体 | |
| JP2009514954A5 (fi) | ||
| US10611729B2 (en) | Farnesoid X receptor antagonists | |
| US8729073B2 (en) | 5-methyl-1-(naphthalen-2-yl)-1H-pyrazole derivatives and their use in potentiating the effect of opioid analgesics | |
| JP6261011B2 (ja) | 眼疾患処置薬 | |
| ES2967119T3 (es) | Compuestos inhibidores de metaloenzimas | |
| JP2007502283A5 (fi) | ||
| JP2008509137A5 (fi) | ||
| JP2007518767A5 (fi) | ||
| JP2006528624A (ja) | Ｐｄｅ４阻害剤として有用なニコチンアミド誘導体 | |
| EP4201405A1 (en) | Pyrrolopyridine derivative and use thereof | |
| EP3562306A2 (en) | Metalloenzyme inhibitor compounds | |
| US20120213867A1 (en) | Raf inhibitors for the treatment of thyroid cancer | |
| WO2006093226A1 (ja) | 止痒剤 | |
| WO2006102363A1 (en) | Methods for treating or preventing acute myelogenous leukemia | |
| WO2005100341A1 (ja) | ２－アミノピリミジン誘導体 | |
| JP2008247878A (ja) | イミダゾピリジンおよびイミダゾピリミジン化合物ならびにそれを含有する麻酔または鎮静薬組成物 | |
| EP1757593A1 (en) | Therapeutic agent for nonviral hepatitis | |
| JP2003267871A (ja) | 放射線障害予防剤 | |
| JPH10101564A (ja) | 鼻炎予防及び／又は治療剤 |